Amarin Corp Plc (AMRN)

[Retired2019]

Down 40% in a month after successful EMA CHMP opinion approval and record Q4 and YOY earnings release. Very Frustrating. I'm not buying Thero said "GIA in the EU" so everyone jumped ship. Until, unless Amarin has any substantial offer worth considering to partner with someone or sell the EU Vazkepa franchise rights, GIA is the only strategy. They can't do nothing, they have to advocate and begin implementing a GIA strategy until the status quo changes. With EMA EC decision imminent (approx. 4 wks), 10 year patent exclusivity, P-CVR label indication, and other trial outcomes data in-progress, maybe the status quo is about to change for shareholders.